Safety and Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma

This study is ongoing, but not recruiting participants.

Sponsored by:	Alcon Research
Information provided by:	Alcon Research
ClinicalTrials.gov Identifier:	NCT00451152

Purpose

Safety, efficacy and duration of effect of Anecortave Acetate for treatment of elevated IOP in patients with open-angle glaucoma.

Condition	Intervention	Phase
Open-Angle Glaucoma	Drug: Anecortave Acetate	Phase II

Genetics Home Reference related topics: early-onset glaucoma

MedlinePlus related topics: Glaucoma

Drug Information available for: Anecortave acetate

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	A Study of the Safety and IOP-Lowering Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma

Further study details as provided by Alcon Research:

Primary Outcome Measures:

Secondary Outcome Measures:

Estimated Enrollment:	81
Study Start Date:	March 2007
Estimated Primary Completion Date:	August 2009 (Final data collection date for primary outcome measure)

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00451152

Locations

United States, Texas
Texas
San Antonio, Texas, United States, 78257

Sponsors and Collaborators

Alcon Research

Investigators

Study Director:

Theresa Landry, Ph.D.

Alcon Research

More Information

Study ID Numbers:	C-06-19
Study First Received:	March 21, 2007
Last Updated:	November 6, 2008
ClinicalTrials.gov Identifier:	NCT00451152
Health Authority:	United States: Food and Drug Administration

Keywords provided by Alcon Research:

glaucoma

Study placed in the following topic categories:

Glaucoma
Eye Diseases
Glaucoma, Open-Angle
Hypertension
Ocular Hypertension

ClinicalTrials.gov processed this record on January 14, 2009